Continuing Education - Satellite Symposia

CE Satellite Symposia

Maryland Room • Located on the Lobby Level of Marriott Wardman Park

Monday, September 9, 2019 • 12:00 PM – 1:15 PM – Lunch Session

Title: Specialty Pharmacy Considerations in the Treatment of Pulmonary Arterial Hypertension

Sponsor: ProCE, Inc. and the NASP Center for Specialty Pharmacy Education (CSPE)

Description: Pulmonary arterial hypertension (PAH) is a relatively rare disease that is often underdiagnosed until significant damage has occurred. Fortunately, understanding of PAH is further increasing and with it, new treatment modalities and recommendations have been put forth. Patients and the entire health care system depend on specialty pharmacies to develop, research, and implement effective patient- and drug-specific clinical and cost-management programs. This activity will provide specialty pharmacists education on developments within the PAH space and perspectives on the cost/benefit equation associated with therapies in the treatment of PAH.

Supporter: This CE activity is supported by an educational grant from Actelion.

For more information, go to


Monday, September 9, 2019 • 6:15 PM – 7:15 PM – Dinner Session

Title: Examining the Use of Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy Treatment

Sponsor: Pharmacy Times Continuing Education™

Description: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a debilitating and degenerative disease in which peripheral nerve damage results in reduced functioning of the extremities. Approximately 30% of patients with CIDP will become wheelchair dependent. The introduction of subcutaneous immunoglobulin as an option in CIDP treatment has created unique changes to the management of the disease. Specialty pharmacists are in a critical position to facilitate appropriate utilization of immunoglobulin by monitoring dosing, administration schedules, rates, and adverse effects.

Supporter: This CE activity is supported by  educational grants from CSL Behring and Grifols.

For more information, go to



Tuesday, September 10, 2019 • 7:00 AM – 8:00 AM – Breakfast Session

Title: Examining Interleukin-17– and Interleukin-23-–Inhibiting Biologics for Psoriasis and Psoriatic Arthritis Treatment

Sponsor: Pharmacy Times Continuing Education™

Description: Psoriasis is a complex inflammatory skin condition affecting more than 8 million Americans and of these, 10% to -30% will develop psoriatic arthritis affecting the joints. The pathophysiology of illness involves immune dysregulation and uncontrolled activation of pro-inflammatory cytokines such as TNFα, IL-17, and IL-23. Treatment strategies involve administration of biologics that block these pathways and subsequently reduce systemic inflammation. Specialty pharmacists should be familiar with all the agents used in the management of psoriatic disease and their crucial role in comprehensive patient education and monitoring throughout treatment. 

Supporter: This CE activity is supported by an educational grant from AbbVie Inc.

For more information, go to


Tuesday, September 10, 2019 • 12:15 PM – 1:15 PM – Lunch Session

Title: Addressing the Needs of Adolescent Patients with Moderate-to-Severe Atopic Dermatitis

Sponsor: Pharmacy Times Continuing Education™

Description: Atopic dermatitis is the most common form of eczema affecting the pediatric and adolescent population. This inflammatory skin disorder manifests in skin creases as erythema and dryness with the hallmark symptom being pruritus. The appearance of these skin lesions and subsequent itching can have a significant effect on patients’ quality of life. Treatment is multifaceted and incorporates nonpharmacologic strategies and pharmacologic therapies, including topical, oral, and subcutaneous agents. Specialty pharmacists need to understand the underlying pathophysiology of the disease and be aware of the current treatment landscape to effectively counsel and monitor therapeutic clinical outcomes.

Supporter: This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

For more information, go to


Tuesday, September 10, 2019 • 6:15 PM – 7:15 PM – Dinner Session

Title: Examining Treatment Strategies for Myasthenia Gravis: A Specialty Pharmacist’s Review

Sponsor: Pharmacy Times Continuing Education™

Description: Myasthenia gravis is a rare autoimmune disease that affects the functionality of the acetylcholine receptor. This disturbance leads to muscle weakness that could affect the eyes, limbs, oropharynx, and diaphragm. A myasthenic crisis is characterized by worsening respiratory function due to weakness of the respiratory muscles, often leading to intubation and in some cases, death. It is likely to be experienced by 15% to 20% of patients with myasthenia gravis. Through this activity, pharmacists will become familiar with myasthenia gravis, its impact on patients, and the current treatment landscape with a focus on specialty medications.

Supporter: This CE activity is supported by educational grants from CSL Behring and Grifols.

For more information, go to



Wednesday, September 11, 2019 • 7:00 AM – 8:00 AM – Breakfast Session

Title: Examining the Economic Data Associated With Early Influenza Intervention With Antiviral Therapy

Sponsor: Pharmacy Times Continuing Education™

Description: Influenza is a highly contagious viral illness that affects hundreds of thousands of people annually and causes significant direct and indirect costs to both the health care system and society. Complications related to this virus, especially in high-risk individuals, can result in prolonged hospitalization and death. While the key mode of protection is vaccination, several antivirals exist for prevention and treatment of the illness. Pharmacists should be aware of the medications used in the prevention and treatment of influenza, including their place in therapy, adverse effect profile, and considerations for patient education to provide optimal care.

For more information, go to


Wednesday, September 11, 2019 • 1:30 PM – 2:30 PM – Lunch Session

Title: Examining Treatments and Best Practices for Specialty Pharmacists in the Care of Patients with Amyotrophic Lateral Sclerosis (ALS)

Sponsor: Pharmacy Times Continuing Education™

Description: Amyotrophic lateral sclerosis (ALS) is characterized by the progressive degeneration of motor nerve cells, and with no known cure, its management typically includes an interdisciplinary approach that considers the physical and psychological needs of the patients and their families or caregivers. Since patients have ongoing interaction with pharmacists when filling prescriptions, pharmacists are often in the unique position to regularly monitor the disease and the effects of treatment as well as ensure the continuity of care recommended by the treatment team. The high cost of disease management as well as direct and indirect costs suggest a critical role for pharmacists as the medication experts on ALS care teams who can take a proactive approach to communication to help manage the disease and appropriately set therapy expectations. In addition to pharmacists’ expanding roles in understanding and monitoring symptomatic and disease-modifying therapies in clinic and inpatient settings, the growing number of potential new medications underscores the importance of ongoing education on the management of ALS.

Supporter: This CE activity is supported by an educational grant from Mitsubishi Tanabe Pharma America, Inc.

For more information, go to